Malvern firm's common warts treatment show promise in mid-stage testing
Aclaris Therapeutics Inc. said Monday its experimental treatment targeting common warts — a condition for which there is no Food and Drug Administration approved medicine — generated positive results in mid-stage testing.
The Malvern, Pa., company said in two phase-II clinical trials that the new drug candidate, a proprietary high-concentration hydrogen peroxide product, met all p rimary and secondary endpoints. In addition, "statistical significance" was seen as early as four weeks after treatment…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: John George Source Type: news
More News: Clinical Trials | Food and Drug Administration (FDA) | Health Management | Statistics | Warts